Midostaurin, Bortezomib and MEC in Relapsed/Refractory Acute Myeloid Leukemia

Targeting aberrant tyrosine kinase activity may impact clinical outcome in acute myeloid leukemia (AML). We conducted a phase I study of the tyrosine kinase inhibitor midostaurin with bortezomib alone and in combination with chemotherapy in patients with AML. Patients on dose levels 1 and 2 (DL1 &am...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Lymphoma
Autori principali: Walker, Alison R., Wang, Hongyan, Walsh, Katherine, Bhatnagar, Bhavana, Vasu, Sumithira, Garzon, Ramiro, Canning, Renee, Geyer, Susan, Wu, Yue-Zhong, Devine, Steven M., Klisovic, Rebecca, Blum, William, Marcucci, Guido
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5360182/
https://ncbi.nlm.nih.gov/pubmed/26784138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1135435
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi